155 related articles for article (PubMed ID: 35007172)
1. Overexpression of protein disulfide isomerase enhances vitamin K epoxide reductase activity.
Chetot T; Benoit E; Lambert V; Lattard V
Biochem Cell Biol; 2022 Apr; 100(2):152-161. PubMed ID: 35007172
[TBL] [Abstract][Full Text] [Related]
2. VKORC1L1, an enzyme rescuing the vitamin K 2,3-epoxide reductase activity in some extrahepatic tissues during anticoagulation therapy.
Hammed A; Matagrin B; Spohn G; Prouillac C; Benoit E; Lattard V
J Biol Chem; 2013 Oct; 288(40):28733-42. PubMed ID: 23928358
[TBL] [Abstract][Full Text] [Related]
3. Two enzymes catalyze vitamin K 2,3-epoxide reductase activity in mouse: VKORC1 is highly expressed in exocrine tissues while VKORC1L1 is highly expressed in brain.
Caspers M; Czogalla KJ; Liphardt K; Müller J; Westhofen P; Watzka M; Oldenburg J
Thromb Res; 2015 May; 135(5):977-83. PubMed ID: 25747820
[TBL] [Abstract][Full Text] [Related]
4. Disulfide-dependent protein folding is linked to operation of the vitamin K cycle in the endoplasmic reticulum. A protein disulfide isomerase-VKORC1 redox enzyme complex appears to be responsible for vitamin K1 2,3-epoxide reduction.
Wajih N; Hutson SM; Wallin R
J Biol Chem; 2007 Jan; 282(4):2626-35. PubMed ID: 17124179
[TBL] [Abstract][Full Text] [Related]
5. Conserved loop cysteines of vitamin K epoxide reductase complex subunit 1-like 1 (VKORC1L1) are involved in its active site regeneration.
Tie JK; Jin DY; Stafford DW
J Biol Chem; 2014 Mar; 289(13):9396-407. PubMed ID: 24532791
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of warfarin resistance using transcription activator-like effector nucleases-mediated vitamin K epoxide reductase knockout HEK293 cells.
Tie JK; Jin DY; Tie K; Stafford DW
J Thromb Haemost; 2013 Aug; 11(8):1556-64. PubMed ID: 23710884
[TBL] [Abstract][Full Text] [Related]
7. VKORC1 and the vitamin K cycle.
Garcia AA; Reitsma PH
Vitam Horm; 2008; 78():23-33. PubMed ID: 18374188
[TBL] [Abstract][Full Text] [Related]
8. VKOR paralog VKORC1L1 supports vitamin K-dependent protein carboxylation in vivo.
Lacombe J; Rishavy MA; Berkner KL; Ferron M
JCI Insight; 2018 Jan; 3(1):. PubMed ID: 29321368
[TBL] [Abstract][Full Text] [Related]
9. The vitamin K oxidoreductase is a multimer that efficiently reduces vitamin K epoxide to hydroquinone to allow vitamin K-dependent protein carboxylation.
Rishavy MA; Hallgren KW; Wilson LA; Usubalieva A; Runge KW; Berkner KL
J Biol Chem; 2013 Nov; 288(44):31556-66. PubMed ID: 23918929
[TBL] [Abstract][Full Text] [Related]
10. Warfarin alters vitamin K metabolism: a surprising mechanism of VKORC1 uncoupling necessitates an additional reductase.
Rishavy MA; Hallgren KW; Wilson L; Singh S; Runge KW; Berkner KL
Blood; 2018 Jun; 131(25):2826-2835. PubMed ID: 29592891
[TBL] [Abstract][Full Text] [Related]
11. A new cell culture-based assay quantifies vitamin K 2,3-epoxide reductase complex subunit 1 function and reveals warfarin resistance phenotypes not shown by the dithiothreitol-driven VKOR assay.
Fregin A; Czogalla KJ; Gansler J; Rost S; Taverna M; Watzka M; Bevans CG; Müller CR; Oldenburg J
J Thromb Haemost; 2013 May; 11(5):872-80. PubMed ID: 23452238
[TBL] [Abstract][Full Text] [Related]
12. [Resistance to acenocoumarol revealing a missense mutation of the vitamin K epoxyde reductase VKORC1: a case report].
Mboup MC; Dia K; Ba DM; Fall PD
Ann Cardiol Angeiol (Paris); 2015 Feb; 64(1):59-61. PubMed ID: 24095214
[TBL] [Abstract][Full Text] [Related]
13. Phylogeny of the Vitamin K 2,3-Epoxide Reductase (VKOR) Family and Evolutionary Relationship to the Disulfide Bond Formation Protein B (DsbB) Family.
Bevans CG; Krettler C; Reinhart C; Watzka M; Oldenburg J
Nutrients; 2015 Jul; 7(8):6224-49. PubMed ID: 26230708
[TBL] [Abstract][Full Text] [Related]
14. Avian interspecific differences in VKOR activity and inhibition: Insights from amino acid sequence and mRNA expression ratio of VKORC1 and VKORC1L1.
Nakayama SMM; Morita A; Ikenaka Y; Kawai YK; Watanabe KP; Ishii C; Mizukawa H; Yohannes YB; Saito K; Watanabe Y; Ito M; Ohsawa N; Ishizuka M
Comp Biochem Physiol C Toxicol Pharmacol; 2020 Feb; 228():108635. PubMed ID: 31639498
[TBL] [Abstract][Full Text] [Related]
15. VKORC1L1, An Enzyme Mediating the Effect of Vitamin K in Liver and Extrahepatic Tissues.
Lacombe J; Ferron M
Nutrients; 2018 Jul; 10(8):. PubMed ID: 30050002
[TBL] [Abstract][Full Text] [Related]
16. VKCFD2 - from clinical phenotype to molecular mechanism.
Czogalla KJ; Watzka M; Oldenburg J
Hamostaseologie; 2016 Nov; 36(Suppl. 2):S13-S20. PubMed ID: 27824210
[TBL] [Abstract][Full Text] [Related]
17. [Vitamin K epoxide reductase: Fresh blood for oral anticoagulant therapies].
Loriot MA; Beaune P
Rev Med Interne; 2006 Dec; 27(12):979-82. PubMed ID: 17070618
[TBL] [Abstract][Full Text] [Related]
18. VKORC1 and VKORC1L1 have distinctly different oral anticoagulant dose-response characteristics and binding sites.
Czogalla KJ; Liphardt K; Höning K; Hornung V; Biswas A; Watzka M; Oldenburg J
Blood Adv; 2018 Mar; 2(6):691-702. PubMed ID: 29581108
[TBL] [Abstract][Full Text] [Related]
19. Identification of the Thioredoxin Partner of Vitamin K Epoxide Reductase in Mycobacterial Disulfide Bond Formation.
Ke N; Landeta C; Wang X; Boyd D; Eser M; Beckwith J
J Bacteriol; 2018 Aug; 200(16):. PubMed ID: 29784887
[TBL] [Abstract][Full Text] [Related]
20. Structural Modeling Insights into Human VKORC1 Phenotypes.
Czogalla KJ; Watzka M; Oldenburg J
Nutrients; 2015 Aug; 7(8):6837-51. PubMed ID: 26287237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
